Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

BACKGROUND: Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction of individual response to treatment remains an unsolved clinical problem. Particularly, administration of an inefficient chemotherapeutic regimen should be avoided. Therefore, a better understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Michlmayr, A, Bachleitner-Hofmann, T, Baumann, S, Marchetti-Deschmann, M, Rech-Weichselbraun, I, Burghuber, C, Pluschnig, U, Bartsch, R, Graf, A, Greil, R, Allmaier, G, Steger, G, Gnant, M, Bergmann, M, Oehler, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967072/
https://www.ncbi.nlm.nih.gov/pubmed/20877360
http://dx.doi.org/10.1038/sj.bjc.6605909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967072/
https://www.ncbi.nlm.nih.gov/pubmed/20877360
http://dx.doi.org/10.1038/sj.bjc.6605909

Ejemplares similares